SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall, M. A.; Beyer, K.; Röhmel, J.; Voigt, S.; Schmitz, J.; Miltenyi, S.; Demuth, I.; Müller, M. A.; Hocke, A.; Witzenrath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.; Corman, V. M.; Giesecke-Thiel, C.; Sander, L. E.; Thiel, A.

doi:10.1038/s41586-020-2598-9

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., & Kurth, F., et al. (2020). SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 1–5.
Added by: Dr. Enrique Feoli (17/10/2020, 19:11) Last edited by: Dr. Enrique Feoli (17/10/2020, 19:11)

Resource type: Journal Article
DOI: 10.1038/s41586-020-2598-9
ID no. (ISBN etc.): 1476-4687
BibTeX citation key: Braun2020
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: Cross immunity
Creators: Baysal, Beyer, Braun, Corman, Demuth, Dingeldey, Drosten, Fauchere, Frentsch, Georg, Giesecke-Thiel, Henze, Hippenstiel, Hocke, Kern, Kruse, Kurth, Lauster, Loyal, Mall, Mangold, Miltenyi, Müller, Reimer, Röhmel, Sander, Schmitz, Suttorp, Thiel, Voigt, Wendisch, Wenschuh, Witzenrath
Collection: Nature

Views: 1/324

Abstract

{Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.}